Adicet Bio, Inc. (ACET) Stock Forecast
ACET analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 6 analysts
- Price target
- $34.83 average of analyst targets
- Upside to target
- +662.2% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-1.56
- 52-week range
- $4.57 – $15.82
ACET analyst ratings
6 analystsNumber of analysts at each rating.
ACET price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ACET earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.58 | −$2.05 | −$1.01 | −$4.64 | +66.0% | 6 |
| Current fiscal year (2026) | −$6.36 | −$8.05 | −$5.11 | −$16.95 | +62.5% | 6 |
| Next fiscal year (2027) | −$4.04 | −$7.67 | $1.07 | −$6.36 | +36.5% | 6 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ACET revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 6 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 6 |
| Next fiscal year (2027) | $28.5M | $0 | $171.1M | 0.0% | 6 |
ACET EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ACET revenue: reported and forecast
ACET EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.51 | −$1.51 | −$1.64 | −$1.58 | −$1.58 | +4.5% | 1 up · 1 down |
| Current fiscal year (2026) | −$8.87 | −$8.80 | −$6.40 | −$6.36 | −$6.36 | −28.3% | 2 up · 0 down |
| Next fiscal year (2027) | −$4.19 | −$3.49 | −$3.95 | −$4.04 | −$4.04 | −3.6% | 2 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ACET earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ACET beat in 7 of 12.
What analysts expect from ACET
6 analysts cover Adicet Bio; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $34.83, 662.2% above the latest close of $4.57. Analysts expect earnings of −$6.36 per share for 2026, +62.5% from a year earlier. For 2027 the average estimate is −$4.04 per share on revenue of $28.5 million. Adicet Bio beat the EPS estimate in 7 of the last 12 quarters.
Related: ACET income statement, ACET key metrics, ACET chart. See the ACET stock overview for the latest quote and news.
ACET forecast FAQ
What is Adicet Bio's price target?
The average analyst price target for Adicet Bio is $34.83, 662.2% above the latest close of $4.57.
Is Adicet Bio a buy, hold or sell?
Of 6 analysts covering Adicet Bio, 6 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Adicet Bio's EPS forecast?
Analysts forecast −$6.36 per share for 2026 (range −$8.05 to −$5.11); for 2027 the estimate is −$4.04.
When does Adicet Bio report earnings?
Adicet Bio is expected to report results for the quarter ending September 30, 2026 on November 4, 2026; the EPS estimate is $-1.56.
Does Adicet Bio usually beat earnings estimates?
Adicet Bio reported EPS at or above the analyst estimate in 7 of the last 12 quarters.